Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy

  • STATUS
    Recruiting
  • End date
    Apr 16, 2026
  • participants needed
    201
  • sponsor
    The Lymphoma Academic Research Organisation
Updated on 16 January 2021
Investigator
Chloé GOURC BERTHOD
Primary Contact
Institut de canc rologie de la Loire (0.0 mi away) Contact
+30 other location
renal function
cyclophosphamide
rituximab
vincristine
ejection fraction
gilbert's syndrome
prednisolone
doxorubicin
neutrophil count
b-cell lymphoma
indolent lymphoma
tazemetostat

Summary

Phase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21.

Phase II of the study is designed to determine the safety and the efficacy of tazemetostat in DLBCL and FL patients :

DLBCL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab FL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab then maintenance with 6 months of tazemetostat and 24 months of Rituximab

Description

Phase I:

Up to 18 patients will be recruited, using a conventional dose-escalation algorithm (3+3 patients per dose level) to identify the maximum tolerated dose (MTD) which will be deemed the RP2D. Patients will receive 8 cycles of RCHOP every 21 days and tazemetostat every day, starting on day 2 of cycle 1.

4 cohorts are defined, according to dose levels of tazemetostat: 400mg Twice a day (BID) (cohort 1, starting level), 600mg BID (cohort 2), 800mg BID (cohort 3), 200mg BID (cohort -1), depending on the observed toxicities.

Phase II:

Up to 184 patients (122 DLBCL and 62 FL) will be recruited and treated with tazemetostat at the MTD and RCHOP.

Patients will receive 6 cycles of RCHOP every 21 days and tazemetostat at the MTD every day, starting on day 2 of cyle 1, + 2 cycles of Rituximab+tazemetostat. For FL, a maintenance of tazemetostat (6 months) + rituximab (24 months) is expected

Details
Treatment Rituximab, cyclophosphamide, vincristine, doxorubicin, Prednisolone, Tazemetostat
Clinical Study IdentifierNCT02889523
SponsorThe Lymphoma Academic Research Organisation
Last Modified on16 January 2021

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 80 yrs?
Gender: Male or Female
Do you have any of these conditions: lymphomas or Lymphoma or Follicular Lymphoma or Lymphoproliferative disorders or Diffuse Large B-Cell Lymphoma or diffuse large b cell lymphoma or Non...?
Do you have any of these conditions: Lymphoma or Lymphoproliferative disorders or lymphomas or diffuse large cell lymphoma or Diffuse Large B-Cell Lymphoma or Follicular Lymphoma or Non-H...?
Do you have any of these conditions: diffuse large b cell lymphoma or Diffuse Large B-Cell Lymphoma or diffuse large cell lymphoma or Lymphoma or Lymphoproliferative Disorder or Non-Hodgk...?
Do you have any of these conditions: Follicular Lymphoma or lymphomas or diffuse large b cell lymphoma or Diffuse Large B-Cell Lymphoma or Lymphoproliferative Disorder or Lymphoproliferat...?
for Cohort DLBCL ONLY
-Patients with an untreated DLBCL de novo or transformed from indolent lymphoma (CD 20 positive) with
Phase Ib aaIPI 2
Phase II: aaIPI 1ONLY
\. Age between 60 and 80 years included
for Cohort FOLLICULAR ONLY
-High Tumor Burden (as defined by GELF criteria > 0) frontline follicular lymphoma (FL) with high risk FLIPI 3-5
\. Aged between 18 years and 80 years included
bis. Females of childbearing potential (FCBP) must agree to use one reliable form of contraception or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 12 months after discontinuation of any study treatments (R-CHOP, tazemetostat, Rituximab)
For both Cohorts
bis- For phase II patients: Bi-dimensionally measurable disease defined by at least one single node or tumor lesion > 1.5 cm assessed by CT scan and/or clinical examination AND a FDG avid disease by PETscan
Life expectancy of 90 days (3 months) before starting tazemetostat
ECOG performance status of 0, 1 or 2 (0 or 1 only for phase Ib)
Adequate renal function as calculated by a creatinine clearance > 40 mL/min by local institutional formula
Signed informed consent
\. Adequate bone marrow function as defined as
ANC 1500/mm3 ( 1.5 X 109/L)
Hemoglobin 9 g/dL (may receive transfusion)
Platelets 75,000/mm3 ( 75 X 109/L) without platelet transfusion dependency during the last 7 days
Total bilirubin 1.5 the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome
\. Adequate liver function as defined as
Alkaline phosphatase (in absence of bone disease), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 X ULN (or 5 X ULN if related to lymphoma involvement)
Patients with prior Hepatitis B and C are eligible if, for Hepatitis B detection, surface antigen is negative and/or HBV DNA is undetectable, and for Hepatitis C detection, if HCV RNA is undetectable
\. Left ventricular ejection fraction (LVEF) 50% of echocardiography or multiple gated acquisition (MUGA) scan
\. Adequate tissue (surgical excision is recommended) for central pathology review and biological caracterisation (see appendix 11
\. Males with partners of childbearing potential must agree to use reliable forms of contraception during 12 months after last treatment administration
\. Patient covered by any social security system (for France only)
\. Patient who understands and speaks one of the country official languages

Exclusion Criteria

for Cohort DLBCL
___15-Previous treatment for B cell lymphoma, except glucocorticoids (no more
than 7 days before inclusion, 1 mg/kg/day max)
for Cohort FOLLICULAR ONLY
bis. Prior therapy for lymphoma including radiotherapy except glucocorticoids (no more than 7 days before inclusion, 1 mg/kg/day max)
-Pregnant or lactating females
For both Cohorts
-Central nervous system or meningeal involvement
-Contraindication to any drug contained in the chemotherapy regimen
-Prior treatment with tazemetostat or other inhibitor of EZH2
-Patients who are undergoing active treatment for another malignancy, exceptions include: A patient who has been disease free for 2 years, or a patient with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible Patients with prior history of myeloid malignancies, including myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia(AML) or prior history of T-LBL/T-ALL are excluded whatever receiving treatment or not and whatever date of diagnosis of these pathologies
-Patients taking medications that are known potent CYP3A4 inducers/inhibitors (including St. John's wort)
-Patients unwilling to exclude St. John's wort, Seville oranges, grapefruit juice and/or grapefruit from diet
-Major surgery within 4 weeks before first dose of study drug (minor procedures including transcutaneous biopsy, central line placement are permitted within 2 weeks of enrollment)
-Inability to take oral medication or malabsorption syndrome or any other uncontrolled gastrointestinal condition that would impare ability to take tazemetostat
-Significant cardiovascular impairment: congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of first dose of tazemetostat or ventricular arrhythmia
-Not applicable
-Active uncontrolled infection requiring systemic therapy
-Congenital immunodeficiency or known HIV (human immunodeficiency virus infection)
-Any other major illness, that in the investigator's judgement, will substantially increase the risk associated with the patient's participation in the study
-Patients who have undergone a solid organ transplant
-Treatment with any investigational drug or device within 30 days before planned first cycle of chemotherapy
-Person deprived of his/her liberty by a judicial or administrative decision
-Adult person under legal protection
-Person hospitalized without consent
-Adult person unabled to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet